Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)-Reference-Cited by-同舟云学术

Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)

Published:2013-09 Issue:9 Volume:37 Page:1016-1020
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Attar Eyal C.,Amrein Philip C.,Fraser James W.,Fathi Amir T.,McAfee Steven,Wadleigh Martha,DeAngelo Daniel J.,Steensma David P.,Stone Richard M.,Foster Julia,Neuberg Donna,Ballen Karen K.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference19 articles.

1. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion;List;N Engl J Med,2006

2. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q;Raza;Blood,2008

3. Persistent malignant stem cells in del(5q) myelodysplasia in remission;Tehranchi;N Engl J Med,2010

4. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome;Braun;Blood,2006

5. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines;Liesveld;Cancer Invest,2011

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-Throughput/High Content Imaging Screen Identifies Novel Small Molecule Inhibitors and Immunoproteasomes as Therapeutic Targets for Chordoma;Pharmaceutics;2023-04-18

2. Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy;Leukemia Research;2022-11

3. From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review;Diagnostics;2021-10-26

4. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach;Expert Opinion on Investigational Drugs;2019-10-22

5. Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-κB activity in hepatocellular carcinoma;Cell Death & Disease;2019-09-26